Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,008 ILa | +0.81% | +6.67% | +117.66% |
Apr. 01 | InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023 | CI |
Mar. 22 | InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months | CI |
Sales 2021 | 219.68 82.22K | Sales 2022 | 388.68 145K | Capitalization | 551M 206B |
---|---|---|---|---|---|
Net income 2021 | 4M 1.5B | Net income 2022 | 44M 16.47B | EV / Sales 2021 | 3,844,919 x |
Net cash position 2021 | 87.64M 32.8B | Net Debt 2022 | 22.37M 8.37B | EV / Sales 2022 | 1,473,908 x |
P/E ratio 2021 |
207
x | P/E ratio 2022 |
12.2
x | Employees | 370 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 64.2% |
Latest transcript on InterCure Ltd.
1 day | +0.81% | ||
1 week | +6.67% | ||
Current month | +2.13% | ||
1 month | +5.55% | ||
3 months | +121.88% | ||
6 months | +133.44% | ||
Current year | +117.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 18-09-30 | |
Amos Cohen
DFI | Director of Finance/CFO | 45 | 20-02-29 |
Boaz Lahav
SAM | Sales & Marketing | - | 22-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ehud Barak
CHM | Chairman | 81 | 18-08-31 |
Chief Executive Officer | 53 | 18-09-30 | |
Director/Board Member | 62 | 20-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.29% | 3 M€ | -35.65% | - | |
0.13% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1,008 | +0.81% | 104,848 |
24-04-25 | 999.9 | +0.77% | 161,024 |
24-04-24 | 992.3 | +5.01% | 104,493 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 30, 2024 at 10:24 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+117.66% | 123M | |
+86.83% | 375M | |
+51.55% | 313M | |
+69.77% | 220M | |
+89.13% | 171M | |
-14.29% | 144M | |
+23.08% | 106M | |
+150.00% | 75.33M | |
-6.02% | 51.09M | |
+11.25% | 74.78M |
- Stock Market
- Equities
- INCR Stock